Viela Bio (Viela Bio) Change In Receivables : $24.62 Mil (TTM As of Dec. 2020)

View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Change In Receivables?

Viela Bio's change in receivables for the quarter that ended in Dec. 2020 was $-2.88 Mil. It means Viela Bio's Accounts Receivable increased by $2.88 Mil from Sep. 2020 to Dec. 2020 .

Viela Bio's change in receivables for the fiscal year that ended in Dec. 2020 was $24.62 Mil. It means Viela Bio's Accounts Receivable declined by $24.62 Mil from Dec. 2019 to Dec. 2020 .

Viela Bio's Accounts Receivable for the quarter that ended in Dec. 2020 was $5.39 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Viela Bio's Days Sales Outstanding for the three months ended in Dec. 2020 was 52.63.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Viela Bio's liquidation value for the three months ended in Dec. 2020 was $324.30 Mil.

Viela Bio Change In Receivables Historical Data

The historical data trend for Viela Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Change In Receivables Chart

Viela Bio Annual Data

Trend

Dec18

Dec19

Dec20

Change In Receivables

-30.00

24.62

Viela Bio Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Change In Receivables	Get a 7-Day Free Trial					-	30.00	-	-2.51	-2.88

Viela Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.62 Mil.

Viela Bio (NAS:VIE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Viela Bio's Days Sales Outstanding for the quarter that ended in Dec. 2020 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5.385	/	9.336	*	91
=	52.63

2. In Ben Graham's calculation of liquidation value, Viela Bio's accounts receivable are only considered to be worth 75% of book value:

Viela Bio's liquidation value for the quarter that ended in Dec. 2020 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	367.687	-	47.429	+	0.75 * 5.385	+	0.5 * 0
=	324.30

Viela Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Viela Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Viela Bio (Viela Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878

Website

https://www.vielabio.com

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

Executives

Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu	director	10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd	10 percent owner	SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund	10 percent owner	CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao	director, officer: Chief Executive Officer	10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz	officer: VP, Head of Commercial	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878